NFKB1 and neoplasm: Besides inhibiting NF-κB, bortezomib inhibited tumor cell growth by targeting cell cycle regulatory proteins, the unfolded protein response (UPR) pathway, p53-mediated apoptosis, and DNA repair mechanisms as well as classical stress response pathways.